LAW – Page 2 – Talk Bio

Merck’s HIV Combo Treatment Advances Towards FDA Filing

1 month ago talkbio0Tagged DOR/ISL, doravirine/islatravir, once-daily, oral regimen, Phase 3 trials, Submission, United States Food and Drug Administration, viral suppression

Doravirine/islatravir (DOR/ISL) combination, Phase 3 trials, Viral suppression, Once-daily oral regimen, FDA submission

ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis’ Lutathera

2 months ago talkbio0Tagged ITM-11, Lutathera, Neoplasms, Neurosecretory Systems, Novartis, Phase 3 COMPETE trial, Radiopharmaceuticals

ITM-11, radiopharmaceutical, Phase 3 COMPETE trial, neuroendocrine tumors, Lutathera, Novartis

Sanofi and Johnson & Johnson’s E. coli Vaccine Candidate Fails in Phase 3 Trial

2 months ago talkbio0Tagged E. coli disease, Escherichia coli, ExPEC9V, Failure (biologic function), Invasive, Johnson & Johnson, Phase 3 trial, sanofi, Vaccines

E. coli vaccine, Sanofi, Johnson & Johnson, Phase 3 trial failure, invasive E. coli disease, ExPEC9V

Biogen Secures $250 Million R&D Funding from Royalty Pharma for Lupus Drug Litifilimab

2 months ago talkbio0Tagged Biogen, Litifilimab, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Vulgaris, Pharma, Phase 3, Phase 3 trials, R&D, Royalty

Biogen, Royalty Pharma, litifilimab, lupus, R&D funding, Phase 3 trials, systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE)

Inventiva Slashes Workforce and Pipeline to Focus on MASH Drug Lanifibranor

2 months ago talkbio0Tagged Inventiva, lanifibranor, MASH, Phase 3 trial, pipeline, restructuring

Inventiva, layoffs, pipeline reduction, lanifibranor, MASH, Phase 3 trial, biotech restructuring

Kura Oncology and Kyowa Kirin Report Positive Phase 2 Results for Ziftomenib in AML, Prepare for FDA Submission

3 months ago talkbio0Tagged Kirin, KOMET-001, Kura Oncology, Kyowa, Leukemia, Myelocytic, Acute, NPM1, NPM1-mutant, Phase 2 trial, Submission, United States Food and Drug Administration, Ziftomenib

Ziftomenib, AML, NPM1-mutant, Phase 2 trial, KOMET-001, FDA submission, Kura Oncology, Kyowa Kirin

Inhibikase Halts Parkinson’s Drug Development After Phase II Failure, Shifts Focus to Pulmonary Arterial Hypertension

3 months ago talkbio0Tagged Clinical Failure, Drug Development, IkT-001Pro, Inhibikase, Parkinson 's disease, Phase 2 Clinical Trials, Pulmonary arterial hypertension, risvodetinib

Inhibikase Therapeutics, risvodetinib, Parkinson’s disease, Phase II trial, clinical failure, drug development, pulmonary arterial hypertension (PAH), IkT-001Pro

Stoke Therapeutics Announces Global Phase 3 EMPEROR Study Design for Zorevunersen in Dravet Syndrome

3 months ago talkbio0Tagged Clinical Research, Cognitive Improvement, EMPEROR, Infantile Severe Myoclonic Epilepsy, Phase 3 trial, regulatory, Seizures, Zorevunersen

Dravet syndrome, zorevunersen, Phase 3 trial, EMPEROR study, seizure reduction, cognitive improvement, regulatory alignment

Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase

3 months ago talkbio0Tagged Bay Area, Biotechnology, Chinese biotechs, Greater, HKEX, IPOs, Kong, listing reforms, Listings

Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.

Repare Therapeutics Advances to Phase 3 Cancer Combo Trial Following Successful MYTHIC Trial Outcomes

3 months ago talkbio0Tagged camonsertib, cancer combo trial, cost-effective clinical trials, lunresertib, Malignant neoplasm of endometrium, MYTHIC, Phase 3 trial, Platinum-Resistant Ovarian Carcinoma, Repare

Repare Therapeutics, Phase 3 trial, cancer combo trial, MYTHIC trial, lunresertib, camonsertib, endometrial cancer, platinum-resistant ovarian cancer, cost-effective clinical trials